Observation of B+ → χc0K+

journal articl

The Causative Constructions in the Finnish Language

2010-03departmental bulletin pape

特集4 : 研究解説 : ゾルゲル法による無機・有機複合材料の機能化

ゾルゲル法によって室温程度の低温で無機材料を合成することができる。この特徴を利用して無機・有機複合材料を合成することができる。この分野のこれまでの研究について解説するとともに、われわれが作製してきた機能性有機化合物を含む新しい無機・有機複合材料について述べる小特集　材料複合化による新機能の創製departmental bulletin pape

Flavonids in Rosmarinus officinalis leaves

P(論文)departmental bulletin pape

Unadjusted relative risks of any early vomiting (95% CI), by age group.

<p>Unadjusted relative risks of any early vomiting (95% CI), by age group.</p

Forest plot of adjusted cumulative risk of early vomiting compared with the 8+8+8 treatment group (8 mg/kg MQ on three consecutive days).

Adjusted analyses were stratified by year and included covariates for age, sex, baseline hematocrit, fever at admission, baseline [log] parasitaemia and vomiting at admission; more specifically to the latter, the occurrence of early vomiting on day 0 for day 1 risk estimates and the occurrence of early vomiting on day 1 for day 2 risk estimates. Cumulative risks were defined as any vomiting on any day within 1 hour of MQ treatment. The cumulative frequency for 8+8+8 was 17/593 (for daily frequencies, see S1 Table).</p

Frequency of adverse events.

<p>Frequency of adverse events.</p

Trial participant baseline characteristics.

<p>Trial participant baseline characteristics.</p

Vomiting frequency (by episode) directly (<1 h) after mefloquine (MQ) administration.

<p>Frequencies are by age group (<b>A-C</b>) and day of treatment.</p

The timing and total dose of MQ (mefloquine) and artesunate from 18 SMRU studies.

<p>The timing and total dose of MQ (mefloquine) and artesunate from 18 SMRU studies.</p